Romain Boidot

[Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance].

Distinct expression of Survivin splice variants in breast carcinomas.

Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.

Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy.

The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas.

Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.

Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.

Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases.

Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis.

Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.

Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors.

A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly.

Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.

Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy.

Transcriptional regulation of the survivin gene.

Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells.

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling.